Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever.
The recent purification and characterization of an interleukin 1-receptor antagonist (IL-1ra) has provided an additional means of elucidating the mechanisms involved in the responses initiated by IL-1. Central administration of IL-1 to rabbits results in a characteristic febrile response and in increased non-rapid-eye-movement sleep (NREMS). In this study, rabbits received various doses of IL-1ra (10-1,000 micrograms) or pyrogen-free saline intracerebroventricularly, and sleep-wake activity and brain temperature (Tbr) were determined for the next 24 h. All doses of IL-1ra tested tended to reduce NREMS in the first postinjection hour with little effect on Tbr. When rabbits were pretreated with 100 micrograms IL-1ra and then injected with 10 ng IL-1, the characteristic IL-1-induced febrile and NREMS-promoting effects were completely blocked.
Opp
M R
MR
Department of Physiology and Biophysics, University of Tennessee, Memphis 38163.
Krueger
J M
JM
D000818:Animals; D004569:Electroencephalography; D005334:Fever / Q000139:chemically induced / Q000517:prevention & control*; D007276:Injections, Intraventricular; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D011506:Proteins / Q000494:pharmacology*; D011817:Rabbits; D011930:Reaction Time; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D012890:Sleep / Q000187:drug effects*; D012894:Sleep Stages / Q000187:drug effects / Q000502:physiology
D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D011506:Proteins; D011994:Recombinant Proteins; D012795:Sialoglycoproteins